Renée JG Arnold, PharmD, RPh

Vice President, Health Economics and Outcomes Research

“I enjoy the challenge of approaching each project with a practiced, but open, mind in terms of methodologies.  It is for this reason, as well as to unite the different specialties involved in health economics and outcomes research, that I co-founded ISPOR over 20 years ago.  This approach often leads to non-formulaic studies using different types of data sources.  I am especially fond of studies that contain elements of real world evidence development.”

Dr. Arnold is a pioneer in the development and use of HEOR methods in comparative effectiveness research. During her 20-plus-year career in the field, she has worked with such Fortune 500 companies as Pfizer, Merck, Lilly, Abbott, Bristol-Myers Squibb, Celgene, Novartis and Sanofi, as well as smaller biotechnology companies, such as Regeneron, BioMarin, Bracco Diagnostics, and Trius Therapeutics, to develop and execute innovative methods of generating and presenting evidence to further adoption of their therapeutic offerings. In particular, Dr. Arnold has developed and promoted use of real-world evidence to support coverage and payment decisions in and outside of the US. She has worked in diverse therapeutic areas, including cardiology, oncology, nephrology, dermatology, pulmonology, endocrinology, infectious diseases, and rare (genetically-based) diseases.

As Vice President of HEOR, Dr. Arnold oversees outcomes research and develops affiliated software for pharmaceutical and federal government programs. Her special interest in evidence-based health derives from her research that deals with use of technology to collect and/or model real-world data for use in rational decision-making by healthcare practitioners and policy makers. Her division continues to present and publish numerous peer reviewed studies that support product uptake, develop novel methods to capture patient-reported outcomes associated with their conditions, and explore opportunities to conduct HEOR studies across the globe.

Dr. Arnold was most recently Principal, IMS Health; President and Co-Founder of Pharmacon International, Inc. Center for Health Outcomes Excellence and President & CEO, Arnold Consultancy & Technology LLC, headquartered in New York City. Her academic titles include Adjunct Associate Professor, Master of Public Health program, Department of Environmental Medicine and Public Health at the Icahn School of Medicine at Mount Sinai in New York City, where she has developed and teaches the pharmacoeconomics coursework. She is also Clinical Instructor, Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado. Dr. Arnold is a founding member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), currently is the Chair of the ISPOR Distance Learning Committee and is an author/co-author of numerous articles and book chapters in the areas of pharmacology, pharmacoeconomics, and cost containment strategies. She is also a recipient and reviewer of U.S. National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grants, as well as a reviewer for Patient-Centered Outcomes Research Institute (PCORI) grant applications and numerous medical journals.


Residency, University of California at San Francisco, San Diego Campus

Doctor of Clinical Pharmacy, University of Southern California

BS, Pre-Pharmacy Studies, University of Maryland

Request a Consultation